首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion
【2h】

Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion

机译:奥沙西m作为UGT2B15的体内探针的证据:奥沙西m清除率因UGT2B15 D85Y多态性而降低但不受UGT2B17缺失的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIMSAlthough in vitro studies indicate that oxazepam is an isoform-selective substrate probe for UDP-glucuronosyltransferase 2B15, the utility of this drug as an in vivo probe is uncertain. The main aim of this study was to determine whether common missense polymorphisms in the UGT2B15 gene (D85Y and K523T) are associated with altered oxazepam pharmacokinetics and pharmacodynamics. We also determined the possible influence of a common deletion polymorphism in the gene encoding UGT2B17, which shows substantial substrate specificity overlap with UGT2B15.
机译:尽管体外研究表明奥沙西m是UDP-葡萄糖醛酸糖基转移酶2B15的同工型选择性底物探针,但该药物作为体内探针的用途尚不确定。这项研究的主要目的是确定UGT2B15基因(D85Y和K523T)中常见的错义多态性是否与奥沙西m的药代动力学和药效学改变有关。我们还确定了常见的缺失多态性在编码UGT2B17的基因中的可能影响,该基因显示与UGT2B15实质性的底物特异性重叠。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号